Table 4b.
Multivariate linear regression analysis of predictors for positive neutralizing antibody levels following the second dose of vaccine in 617 participants, 420 ICPs and 197 immunocompetent controls.
| Effect | Ratio of mean | Lower 95% CI | Upper 95% CI | P-value |
|---|---|---|---|---|
| Gender, male | 0.83 | 0.65 | 1.08 | 0.16 |
| Age | 0.98 | 0.98 | 0.99 | 0.0002 |
| HIV | 0.91 | 0.62 | 1.32 | 0.61 |
| Solid malignancies | 0.57 | 0.34 | 0.98 | 0.04 |
| Multiple myeloma | 0.69 | 0.45 | 1.07 | 0.09 |
| HSCT | 1.35 | 0.77 | 2.36 | 0.29 |
| Liver transplant | 0.54 | 0.27 | 1.06 | 0.07 |
| Myelodysplastic disorders | 0.95 | 0.50 | 1.82 | 0.88 |
| CLL/NHL | 0.58 | 0.38 | 0.87 | 0.008 |
| Kidney transplant | 0.19 | 0.11 | 0.34 | < 0.0001 |
| Heart transplant | 0.11 | 0.04 | 0.31 | < 0.0001 |
RBD – receptor binding domain, CI – confidence interval, HIV - human immunodeficiency virus, HSCT - hematopoietic stem cell transplant, CLL – chronic lymphatic leukemia, NHL – non-Hodgkin's lymphoma, ICPs – Immunocompromised patients.